Expression and clinical significance of HMGA2 in renal carcinoma
10.3760/cma.j.issn.0253-3766.2017.02.010
- VernacularTitle: 高迁移率族蛋白A2在肾癌中的表达及临床意义
- Author:
Ying LIU
1
;
Qizhong FU
2
;
Lin PU
2
;
Lingling SONG
2
;
Guangyao LYU
2
;
Jing LIU
2
;
Zhenlong WANG
3
;
Ziming WANG
3
Author Information
1. Xi′an Jiaotong University Health Science Center, Xi′an, 710049, China
2. Department of Urological Surgery, the Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China
3. Department of Urological Surgery, the Second Affiliated Hospital of Xi′an Jiaotong University, Xi′an, 710004, China
- Publication Type:Clinical Trail
- Keywords:
Renal neoplasms;
High mobility group A2;
Immunohistochemistry;
Clinicopathological features;
Diagnosis;
Prognosis
- From:
Chinese Journal of Oncology
2017;39(2):127-132
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To detect the high mobility group A2 (HMGA2) expression in renal carcinoma, and to explore the relationship with clinicopathological features and its significance for prognosis.
Methods:50 renal carcinoma specimens, 50 corresponding adjacent normal kidney tissue samples, and 40 benign renal tumor specimens were used in this study. The expressions of HMGA2 mRNA and protein were detected by RT-PCR, Western blot and immunohistochemical assays, and its relationship with clinicopathological features and prognosis in the renal carcinoma patients was analyzed.
Results:The RT-PCR results showed that the relative expression levels of HMGA2 mRNA in the renal carcinoma, benign renal tumor tissues, and adjacent normal renal tissues were 0.84±0.23, 0.19± 0.06 and 0.08±0.04, respectively, and the expression in renal carcinoma tissue was significantly higher than those of the other 2 groups (P<0.01). The Western blot results showed that the relative expression levels of HMGA2 protein in the renal carcinoma, benign renal tumor tissues, and adjacent normal renal tissues were 0.91±0.24, 0.12±0.04 and 0.03±0.01, respectively, and the expression in renal carcinoma tissue was significantly higher than those of the other 2 groups (P<0.01). Immunohistochemical results showed that the expression of HMGA2 protein exhibited brown and tan granular, which mainly distributed in the cell nuclei. Among the 50 cases of renal carcinoma, 34 cases exhibited positive expression, with a positive rate of 68.0%. Among the 40 cases of benign tumor tissues, 3 cases had positive expression, with a positive rate of 7.5%, while among the 50 cases of adjacent normal renal tissues, there was only 1 case exhibiting positive expression of HMGA2 protein, with a positive rate of 2.0%. The protein expression of HMGA2 was significantly higher in the renal carcinoma than in the benign tumors and normal renal tissues (P=0.004). There was no statistically significant difference in the association of HMGA2 protein expressions with age, sex, tumor size and histological type (P>0.05), while significant difference did exist in the association with different statuses of TNM staging and lymph node metastasis (P<0.05). The median time to progression (TTP) in 34 HMGA2 protein-positive patients was (22.36±1.48) months and that of 16 HMGA2 protein-negative patients was (34.55±1.87) months (P<0.05).
Conclusions:HMGA2 plays an important role in the tumorigenesis and development of renal carcinoma, and may be used as an important predictor for estimating the prognosis of renal carcinoma. HMGA2 might become a new diagnostic and prognostic marker for renal carcinoma.
